Personalized Acromegaly Treatment Platform

Publication ID: 24-11857595_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Acromegaly Treatment Platform,” Published Technical Disclosure No. 24-11857595_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857595_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,595.

Summary of the Inventive Concept

A next-generation system integrating AI, bioinformatics, and precision medicine to optimize acromegaly treatment outcomes, enhancing patient quality of life and reducing healthcare costs.

Background and Problem Solved

The original patent for oral drug delivery of octreotide addressed a significant need in acromegaly treatment. However, it had limitations in terms of individualized treatment regimens, dosage optimization, and real-time biomarker feedback. The present inventive concept overcomes these limitations by leveraging cutting-edge technologies to create a personalized treatment platform.

Detailed Description of the Inventive Concept

The inventive concept comprises a bioinformatics module analyzing genomic data and medical history to predict optimal treatment regimens. An AI-powered dosage optimization module adjusts octreotide administration schedules based on real-time biomarker feedback from wearable devices or nanoparticle-based formulations. This enables precision medicine-based acromegaly management, where customized octreotide formulations and dosages are tailored to individual receptor profiles and disease severity.

Novelty and Inventive Step

The new claims introduce a paradigm shift in acromegaly treatment by integrating AI, bioinformatics, and precision medicine. The inventive concept's novelty lies in its ability to provide personalized treatment regimens, real-time biomarker feedback, and optimized dosage administration, which are not addressed by the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include integrating additional data sources, such as electronic health records or medical imaging, to further enhance treatment personalization. Variations may involve using different AI algorithms or machine learning models to optimize dosage administration.

Potential Commercial Applications and Market

The personalized acromegaly treatment platform has significant commercial potential in the pharmaceutical and healthcare industries, offering a competitive advantage in the treatment of rare diseases. The market for precision medicine-based treatments is growing rapidly, and this inventive concept is poised to capitalize on this trend.

CPC Classifications

SectionClassGroup
A A61 A61K38/08
A A61 A61K9/0053
A A61 A61K9/4858
A A61 A61K38/31
A A61 A61P5/06

Original Patent Information

Patent NumberUS 11,857,595
TitleMethod of treating diseases
Assignee(s)Amryt Endo, Inc.